Consortium of Eosinophilic Gastrointestinal Disease Researchers-HEROs Supplement

项目总结/摘要 这项嗜酸性胃肠研究者联盟（CEGIR）研究将招募约150名 家庭评估SARS-COV-2如何不同地影响嗜酸性胃肠炎儿童 与没有这些疾病的儿童相比。拟议的工作是更大的一部分 人类流行病学和对SARS-CoV-2的反应（HEROS）研究，该研究允许比较 患有特应性疾病的儿童和没有这些疾病的儿童。虽然哮喘还没有 被确定为严重COVID-19疾病的明确风险因素，有证据表明，患有哮喘的儿童 和其它特应性病症对病毒性呼吸道感染的易感性增加（Esquivel et al，AJRCCM，PMC 5649984），病毒性呼吸道感染可能导致基础疾病恶化， 气道疾病（Jartti等，J Allergy Clin Immunol，PMID 28987219）。目前没有数据表明， 这是否适用于SARS-CoV-2感染，或者过敏性气道疾病是否可能 保护性的登记的家庭将参加6个月的调查和生物样本 收藏.这些儿童及其家人已经参加了CEGIR NIH资助的研究， 因此，将克服临床研究实施的许多挑战。这项拟议的工作 仍在母合同的范围内，并响应NOT-AI-20-031。

Project Summary/Abstract This Consortium of Eosinophilic Gastrointestinal Researchers (CEGIR) study will enroll approximately 150 families to assess how SARS-COV-2 differentially affects children with Eosinophilic Gastrointestinal Disorders (EGIDs) compared to children without these disorders. The proposed work is part of the larger Human Epidemiology and Response to SARS-CoV-2 (HEROS) study that allows a comparison between children with atopic conditions and children without those conditions. Although asthma has not been identified as a clear risk factor for severe COVID-19 disease, there is evidence that children with asthma and other atopic conditions have increased susceptibility to viral respiratory infections (Esquivel et al, AJRCCM, PMC5649984) and that viral respiratory infections may result in worsening of underlying airway disease (Jartti et al, J Allergy Clin Immunol, PMID 28987219). No data currently exist as to whether this is true for SARS-CoV-2 infection or whether allergic airway disease could be protective. Enrolled families will participate for 6 months completing surveys and biological sample collections. These children and their families are already enrolled in the CEGIR NIH funded studies and therefore will overcome many challenges for clinical study implementation. This proposed work remains in scope to the parent award and is responsive to the NOT-AI-20-031.